WallStreetZenWallStreetZen

NASDAQ: SYRS
Syros Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for SYRS

Based on 5 analysts offering 12 month price targets for Syros Pharmaceuticals Inc.
Min Forecast
$10.00+102.84%
Avg Forecast
$16.20+228.6%
Max Forecast
$20.00+305.68%

Should I buy or sell SYRS stock?

Based on 5 analysts offering ratings for Syros Pharmaceuticals Inc.
Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SYRS stock forecasts and price targets.

SYRS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Piper Sandler
Top 9%
92
Strong BuyMaintains$20.00+305.68%2023-01-05
JMP Securities
Bottom 9%
9
BuyMaintains$16.00+224.54%2022-11-15
Oppenheimer
Bottom 15%
15
BuyMaintains$15.00+204.26%2022-11-15
HC Wainwright & Co.
Top 9%
92
BuyMaintains$20.00+305.68%2022-11-15
Alliance Global Partners
Bottom 33%
33
Strong BuyMaintains$10.00+102.84%2022-05-17

1 of 1

Forecast return on equity

Is SYRS forecast to generate an efficient return?
Company
N/A
Industry
0.02%
Market
13.26%

Forecast return on assets

Is SYRS forecast to generate an efficient return on assets?
Company
N/A
Industry
0.14%

SYRS earnings per share forecast

What is SYRS's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.51
Avg 2 year Forecast
-$0.94
Avg 3 year Forecast
$0.18

SYRS revenue forecast

What is SYRS's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$16.1M-31.52%
Avg 2 year Forecast
$59.5M+153.67%
Avg 3 year Forecast
$167.4M+614.24%
SYRS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SYRS revenue growth forecast

How is SYRS forecast to perform vs Biotechnology companies and vs the US market?
Company
89.33%
Industry
38.69%
Market
9.2%
SYRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SYRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SYRS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SYRS$4.93$16.20+228.60%Strong Buy
EVLO$0.91$3.25+257.14%Hold
EYEN$2.76$12.00+334.78%Buy
EIGR$2.26$48.00+2,023.89%Strong Buy
SCLX$7.60N/AN/A

Syros Pharmaceuticals Stock Forecast FAQ

Is Syros Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: SYRS) stock is to Strong Buy SYRS stock.

Out of 5 analysts, 2 (40%) are recommending SYRS as a Strong Buy, 3 (60%) are recommending SYRS as a Buy, 0 (0%) are recommending SYRS as a Hold, 0 (0%) are recommending SYRS as a Sell, and 0 (0%) are recommending SYRS as a Strong Sell.

If you're new to stock investing, here's how to buy Syros Pharmaceuticals stock.

What is SYRS's earnings growth forecast for 2023-2025?

(NASDAQ: SYRS) Syros Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 21.89%.

Syros Pharmaceuticals's earnings in 2023 is -$113,693,000.On average, 4 Wall Street analysts forecast SYRS's earnings for 2023 to be -$30,541,141, with the lowest SYRS earnings forecast at -$53,396,431, and the highest SYRS earnings forecast at -$7,281,332. On average, 3 Wall Street analysts forecast SYRS's earnings for 2024 to be -$19,012,366, with the lowest SYRS earnings forecast at -$39,845,064, and the highest SYRS earnings forecast at -$8,090,368.

In 2025, SYRS is forecast to generate $3,640,666 in earnings, with the lowest earnings forecast at -$8,090,368 and the highest earnings forecast at $25,282,401.

What is SYRS's revenue growth forecast for 2023-2025?

(NASDAQ: SYRS) Syros Pharmaceuticals's forecast annual revenue growth rate of 89.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.69%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.2%.

Syros Pharmaceuticals's revenue in 2023 is $23,436,000.On average, 4 Wall Street analysts forecast SYRS's revenue for 2023 to be $324,626,032, with the lowest SYRS revenue forecast at $161,807,368, and the highest SYRS revenue forecast at $436,879,894. On average, 2 Wall Street analysts forecast SYRS's revenue for 2024 to be $1,202,431,003, with the lowest SYRS revenue forecast at $212,372,171, and the highest SYRS revenue forecast at $2,192,489,836.

In 2025, SYRS is forecast to generate $3,385,616,916 in revenue, with the lowest revenue forecast at $750,381,669 and the highest revenue forecast at $8,579,835,688.

What is SYRS's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: SYRS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.14%.

What is SYRS's Price Target?

According to 5 Wall Street analysts that have issued a 1 year SYRS price target, the average SYRS price target is $16.20, with the highest SYRS stock price forecast at $20.00 and the lowest SYRS stock price forecast at $10.00.

On average, Wall Street analysts predict that Syros Pharmaceuticals's share price could reach $16.20 by Jan 5, 2024. The average Syros Pharmaceuticals stock price prediction forecasts a potential upside of 228.6% from the current SYRS share price of $4.93.

What is SYRS's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: SYRS) Syros Pharmaceuticals's current Earnings Per Share (EPS) is -$16.31. On average, analysts forecast that SYRS's EPS will be -$1.51 for 2023, with the lowest EPS forecast at -$2.64, and the highest EPS forecast at -$0.36. On average, analysts forecast that SYRS's EPS will be -$0.94 for 2024, with the lowest EPS forecast at -$1.97, and the highest EPS forecast at -$0.40. In 2025, SYRS's EPS is forecast to hit $0.18 (min: -$0.40, max: $1.25).

What is SYRS's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: SYRS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.